

Bisphosphonates for the Prevention and Treatment of Postmenopausal Osteoporosis

by Janet Espirito, Pharm.D.

References

1. Osteoporosis prevention, diagnosis, and therapy. NIH consensus statement 2000 March 27-29;17(1):1-45.
2. National Osteoporosis Foundation. Physicians Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Excerpta Medica Inc; 1999.
3. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. *J Bone Miner Res* 1997;12(1):24-35.
4. Watts NB. Treatment of osteoporosis with bisphosphonates. *Rheum Dis Clin North Am* 2001 February;27(1):197-214.
5. Rosen CJ, Kessenich CR. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. *Drugs* 1996 April;51(4):537-51.
6. Alendronate [package insert]. Merck & Co., Inc., Whitehouse Station, NJ. October 2000.
7. Risedronate [package insert]. Proctor & Gamble Pharmaceuticals, Cincinnati, OH. August 2000.
8. Etidronate [package insert]. Proctor & Gamble Pharmaceuticals, Cincinnati, OH. August 1998.
9. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. *Drug Saf* 1996 March;14(3):158-70.
10. Kleerekoper M, Schein JR. Comparative safety of bone remodeling agents with a focus on osteoporosis therapies. *J Clin Pharmacol* 2001;41(3):239-50.
11. Eastell R. Treatment of postmenopausal osteoporosis. *N Engl J Med* 1998 March 12;338(11):736-46.
12. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. *JAMA* 2001 March 21;285(11):1415-8.
13. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. *N Engl J Med* 1990 July 12;323(2):73-9.
14. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. *Am J Med* 1993 December;95:557-567.
15. Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. *Am J Med* 1997 December;103:468-476.

(Continued on next page)

A University of Washington / Harborview Medical Center Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2002 by the University of Washington
Also published on the World Wide Web at <http://uw.prnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

Bisphosphonates for Postmenopausal Osteoporosis (cont.)

References (continued)

16. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. *N Engl J Med* 1995 November 30;333(22):1437-43.
17. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet* 1996 December 7;348:1535-41.
18. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. *JAMA* 1998 December 23/30;280(24):2077-82.
19. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. *Osteoporos Int* 1999;9(5):461-8.
20. Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. *N Engl J Med* 1998 February 19;338(8):485-92.
21. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. *J Clin Endocrinol Metab* 1998;83(2):396-402.
22. Fogelman I, Ribot C, Smith R. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. *J Clin Endocrinol Metab* 2000;85(5):1895-1900.
23. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. *JAMA* 1999 October 13;282(14):1344-1352.
24. Reginster JY, Minne HW, Sorensen OH. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. *Osteoporos Int* 2000;11(1):83-91.
25. Harris ST. Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate. *Osteoporos Int* 2001; Suppl 3:S11-6.
26. Watts NB. Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials. *Osteoporos Int* 2001; Suppl 3:S17-22.
27. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once weekly and alendronate 10mg daily in the treatment of osteoporosis. *Aging Clin Exp Res* 2000;12(1):1-12.
28. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. *Am J Gastroenterol* 2002;97(1):58-64.
29. Thiebaud D, Burckhardt P, Melchior J, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. *Osteoporos Int* 1994; 4(2):76-83.
30. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. *N Engl J Med* 2002 February 28;346(9):653-61.